| Date | Title | Description |
| 14.04.2025 | Cellestia Biotech spins-off Anciata Therapeutics |
Anciata Therapeutics, Inc. is a special purpose company created to develop IPX-2017, a novel, orally administered therapeutic to clinical proof of concept for the treatment of autoimmune disorders. Anciata Therapeutics is fully financed by... |
| 01.07.2024 | Dubai's TVM Capital backs healthcare player from Saudi-focused fund | Premium
Helmut Schuehsler, chairman and CEO, TVM Capital Healthcare
TVM Capital Healthcare, an emerging markets-focused healthcare private equity firm, has backed a Saudi Arabian bio-generic drugs manufacturing company, marking the fourth d... |
| 29.05.2024 | $250 M Saudi-focused Afiyah Fund launched by TVM Capital Healthcare | The TVM Healthcare Afiyah Fund LP, which is the company’s second Middle Eastern capital pool, closed today at a cost of roughly $250 million. TVM Capital Healthcare is an international healthcare expansion and growth capital investor.
Since... |
| 28.05.2024 | Singapore's TVM Capital raises $250m for Saudi healthcare fund | Dubai- and Singapore-headquartered healthcare private equity firm TVM Capital Healthcare said on Tuesday it had raised around $250 million for its fund that focuses on investing in Saudi Arabia’s healthcare sector. |
| 25.04.2024 | TVM Capital Healthcare led $ 17 M received by mental health care platform Neurocare | The Munich-based neurocare group AG (neurocare), a pioneer in individualized mental health care that offers tools to enable clinicians to provide the best care possible to their patients, has received a $17 million investment from TVM Capit... |
| 22.04.2024 | Munich's Smart Reporting secures €23M Series C for AI-supported medical software | Munich healthtech company Smart Reporting has successfully completed a financing round of €23 million, bringing its funding to over €60 million.
Smart Reporting was founded in 2014 as a spin-off from Ludwig-Maximilians-Universität (LMU).
An... |
| 22.04.2024 | “Messen waren beim Fundraising der Schlüssel zum Erfolg” | Das Berliner Startup myo, 2018 von Jasper Böckel gegründet, positioniert sich als Kommunikationsplattform für Pflegeheime. “Begonnen hat alles mit der Kommunikation zwischen Mitarbeitenden im Pflegeheim und den Angehörigen der Pflegebedürft... |
| 13.03.2024 | TVM Capital Life Science to Participate in LSI USA ’24 Emerging Medtech Summit 2024 | - |
| 06.02.2024 | TVM Capital Life Science Co-Leads $16 Million Series A Financing Round for Vektor Medical to Revolutionize Arrhythmia Care | MUNICH, Germany and MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced a $16 million Series A financ... |
| 31.01.2024 | Berlin-based Myosotis secures €8M Series A funding for digital aged care | TVM Capital Life Science today announced the closing of an €8 million Series A financing round for Berlin-based digital healthcare startup Myosotis.
Myosotis (also known as myo) was founded in 2018 to relieve employees in care homes through... |
| 21.02.2023 | Esperas Pharma, Inc. Announces Investment from TVM Life Science Innovation I and The Fonds de solidarité FTQ | Montréal, Québec, February 21, 2023 – Esperas Pharma, Inc. (“Esperas”), a company based in Montréal, Québec, today announced a follow-on investment by TVM Capital Life Science (“TVM”) through its fund TVM Life Science Innovation I SCSp and ... |
| 01.02.2023 | TVM Capital Life Science announces up to USD 24 million investment in oncology company, Recurv Pharma, Inc. | Recurv is the 8th early-stage or product focused company (PFC) investment for TVM Life Science Innovation II Fund
Recurv is developing novel taxane, RP-001, against solid tumors
RP-001 delivered in nano-emulsion formulation, focusing drug... |
| 18.12.2022 | TVM Capital Winter Conference | Dear Friends and Partners of TVM Capital Life Science.
We have decided to cancel the 2023 TVM Winter Conference in Kitzbuehel.
The decision to cancel our 2023 Winter Conference was not easy, but the health and safety of our guests are of ... |
| 18.01.2022 | TVM Capital Life Science promotes Dr. Sascha Berger and Dr. Alain Thibault to General Partner | Munich, Germany / Montreal, Canada – 12 January 2022 – TVM Life Science (“TVM”),
a leading International Life Sciences Venture Capital firm, today announces the formal
promotion of Dr. Sascha Berger and Dr. Alain Thibault to General Partner... |
| 18.03.2021 | TVM Capital Healthcare raising $500m for two funds targeting SE Asia, Middle-East | Premium
TVM Capital Healthcare (TVMCH), the UAE arm of German investment firm TVM Capital, is raising a total of $500 million across two separate funds targeting to invest in the Middle-East and Southeast Asia, DealStreetAsia has learnt.
Co... |
| 29.10.2020 | TVM Capital Life Science closes its new fund on $478m | TVM Capital Life Science has held the $478m final close of its second Innovation fund, which will back life science comp |
| 27.10.2020 | TVM Capital Life Science Announces Substantially Oversubscribed US$478 Million Final Closing of TVM Life Science Innovation II, largest fund in the firm’s history | Munich/Montreal: October 27, 2020 – TVM Capital Life Science, one of the leading life sciences venture capital firms in North America and Europe, today announced the final closing of its latest fund, TVM Life Science Innovation II (TVM LSI ... |
| 20.09.2017 | TVM Capital Life Science hosts its 6th annual Life Science Conference in Montreal | Montreal, September 19, 2017
TVM Capital Life Science convened its 6th annual Autumn Conference in Montreal yesterday, with more than 200 international attendees from Asia, the United States, Europe and Canada who networked with senior dec... |
| 13.06.2017 | CENTOGENE raises a EUR 25 million Series A financing to fuel innovation and to accelerate growth into personalized medicine | Rostock/Berlin, 13.06.2017 – CENTOGENE AG, a worldwide leader in the field of genetic diagnostics for rare diseases, announced today its 25 million EUR Series A financing round led by TVM Capital Life Science in collaboration with DPE Deuts... |
| 07.12.2016 | Neurimmune and TVM Capital Life Science Announce Creation of AL-S Pharma to Develop Innovative Therapy for Patients with ALS | Schlieren, Switzerland, and Munich, Germany, December 07, 2016 / B3C newswire / — Neurimmune and TVM Capital Life Science’s latest fund, TVM Life Science Ventures VII, today announced their investment in AL-S Pharma AG, a company based in S... |
| 05.12.2016 | Pfizer Ventures and TVM Life Science Ventures VII Announce Additional Investment in Ixchelsis Ltd. | London, UK, December 05, 2016 / — Pfizer Venture Investments (PVI) and TVM Life Science Ventures VII today announced that they are making an additional $12M investment in Ixchelsis Ltd, a start-up company based at Discovery Park, Sandwich, ... |
| 19.09.2016 | TVM Life Science Ventures VII Announces Investment in AurKa Pharma Inc. | Montréal, Québec, September 19th, 2016 –TVM Life Science Ventures VII today announced the fund’s twelfth investment establishing AurKa Pharma Inc., a company based in Montréal, Québec. AurKa Pharma Inc. plans to develop, to proof-of-concept... |
| 25.07.2016 | FDA grants QIDP and Fast Track Designations to MCB3837, Morphochem’s novel intravenous antibacterial to treat C. difficile infections | Munich (Germany), July 25, 2016 — Morphochem, a clinical-stage pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has designated Morphochem’s intravenous (IV) antibacterial product candidate MCB3837 as ... |
| 22.06.2016 | Morphochem’s Investigational New Drug (IND) application accepted by the FDA – Novel antibacterial for intravenous treatment of Clostridium difficile infections (CDI), MCB3837/MCB3681, can now move int... | Munich, Germany, June 22, 2016 — Morphochem, a private clinical-stage pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) Application for the company’s nov... |
| 12.05.2016 | TVM Capital Healthcare Partners named Best Private Equity Firm by Banker Middle East | United Arab Emirates, 12 May 2016: TVM Capital Healthcare Partners, a private equity firm focused on emerging markets and dedicated to healthcare investments, announced today that it has been recognised as the “Best Private Equity Firm” at ... |
| 14.04.2016 | Esperas Pharma Inc. will begin clinical development of a new anti-cancer product at major Montreal hospitals | Montréal, Québec, April 11 2016 – Esperas Pharma Inc. (“Esperas”) today announced the initiation of a project to develop a new oral anticancer agent called ESP-01, in partnership with Quebec Clinical Research Organization in Cancer (Q-CROC)... |
| 06.10.2014 | TVM Capital Life Science closes $201.6 mln for fund | - |
| 06.10.2014 | TVM Capital Life Science closes Fund VII at $202 mln | - |
| 15.04.2014 | Rapid Micro Biosystems Closes Additional Funding | Rapid Micro Biosystems, a Bedford, MA-based provider of automated, non-destructive, rapid microbial detection for quality control testing of pharmaceutical and personal care products, closed on additional funding of undisclosed amount.
Back... |
| 02.12.2013 | TVM Capital Life Science enters into Collaboration with Hanwha Biologics | Montreal/Seoul, December 2, 2013 – TVM Capital Life Science and Hanwha Chemical Corporation Biologics Business Unit (“Hanwha Biologics”) announced today that both parties entered into a global collaboration agreement. TVM Capital Life Scien... |
| 04.11.2013 | TVM Capital to focus on Life Science Venture and Healthcare Private Equity Investing only | Two independent investment teams to focus on Life Science Venture Capital investments in Western Europe and North America and on Healthcare Private Equity investments in the MENA region
Vienna, 04.November 2013 – During BioEurope 2013 in V... |
| 04.10.2013 | TVM Capital Life Science to collaborate with the Korea Drug Development Fund to support the pharmaceutical industry in Korea | Munich/Montreal/Seoul, September 30, 2013 – TVM Capital Life Science announced today that the company entered into an MOU with the Korea Drug Development (“KDDF”) to support Korea’s ability to develop new drugs that meet global standards. T... |
| 29.06.2013 | Rapid Micro Biosystems Raises $32.6M in Series B Financing | Rapid Micro Biosystems, a Bedford, MA-based provider of microbial detection for quality control testing within the pharmaceutical and personal care products market segments, raised $32.6m in Series B financing.
The round was led by Longitud... |
| 27.07.2012 | Fundraising: Gene therapy firm targeting sickle cell anemia raises $60M | Product: Gene therapy to target sickle cell anemia, beta-thalassemia and childhood cerebral adrenoleukodystrophy
Money raised: $60 million in series D; at least $76 million in previous rounds based on press releases and U.S. Securities and ... |
| 16.09.2008 | CommProve Secures New Financing of $14 Million | Financing round to accelerate international expansion and product extension
16th September 2008 - CommProve, a leading vendor of advanced solutions for the real-time monitoring of wireless networks, has closed $14 Million in new financing t... |
| 19.08.2008 | Bitwave raises $10 million for reconfigurable transceiver chips | Bitwave Semiconductor has raised $10 million to help get its first chip to market after five years of development.
Investors included Apex Venture Partners, ECentury Capital Partners, and TVM Capital. Those same investors provided the $13 m... |
| 23.05.2008 | Networking chip firm Arteris raises $7.5 million | Arteris has raised $7.5 million in a third round of financing to fund its networking chip technology.
DoCoMo capital came aboard as a new investor, joining existing investors Crescendo Ventures, TVM Capital, Ventech and Synopsis Inc. in the... |
| 25.01.2008 | Life sciences briefing: Friday, Jan. 25, 2008 | TODAY’S HEADLINES:
Health-info site HealthCentral Network pulls in $50M (paidContent)
BrightHeart Vet corrals $29M to acquire animal hospitals (release)
AviaraDx raises $8M for cancer diagnostics (peHUB)
Valor Medical aims for $15M for brai... |
| 03.05.2007 | Noxxon Pharma draws $50M for aptamer drugs | Noxxon Pharma, a Berlin-based biotech, raised 37 million euros ($50 million) to help push its first aptamer-based drug candidates for kidney and eye disease into clinical trials.
The main new investors included TVM Capital, Sofinnova Partne... |
| - | 2019 TVM Capital Winter Conference |
Celebrate with us our 11th biennial Winter Conference in February 2019 where we will discuss the ‘New Champions in Life Science’.
The purpose of this biennial event is to provide a high profile platform for networking and strategic discu... |
| - | 2022 TVM Capital Winter Conference | Dear Friends and Partners of TVM Capital Life Science.
In light of the ongoing (COVID-19) coronavirus outbreak and the resulting travel restrictions, we have decided to postpone the TVM Winter Conference in Kitzbuehel, initially scheduled ... |
| - | Fundraising: Gene therapy firm targeting sickle cell anemia raises $60M | Company name: bluebird bio.
Industry: Biotechnology.
Location: Cambridge, Massachusetts.
Product: Gene therapy to target sickle cell anemia, beta-thalassemia and childhood cerebral adrenoleukodystrophy
Money raised: $60 million in series D;... |